BR0316948A - Composto, formulação farmacêutica, e, uso de um composto - Google Patents

Composto, formulação farmacêutica, e, uso de um composto

Info

Publication number
BR0316948A
BR0316948A BR0316948-0A BR0316948A BR0316948A BR 0316948 A BR0316948 A BR 0316948A BR 0316948 A BR0316948 A BR 0316948A BR 0316948 A BR0316948 A BR 0316948A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical formulation
amelioration
diastereomers
enantiomer
Prior art date
Application number
BR0316948-0A
Other languages
English (en)
Portuguese (pt)
Inventor
James Ronald Gillig
Lawrence Joseph Heinz
Michael Dean Kinnick
Yen-Shi Lai
John Michael Junior Morin
Nancy June Snyder
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0316948A publication Critical patent/BR0316948A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0316948-0A 2002-12-11 2003-12-03 Composto, formulação farmacêutica, e, uso de um composto BR0316948A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43270102P 2002-12-11 2002-12-11
PCT/US2003/037071 WO2004052848A1 (en) 2002-12-11 2003-12-03 Novel mch receptor antagonists

Publications (1)

Publication Number Publication Date
BR0316948A true BR0316948A (pt) 2005-10-18

Family

ID=32507985

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316948-0A BR0316948A (pt) 2002-12-11 2003-12-03 Composto, formulação farmacêutica, e, uso de um composto

Country Status (9)

Country Link
US (1) US7132456B2 (https=)
EP (1) EP1572637A1 (https=)
JP (1) JP2006509801A (https=)
CN (1) CN1726189A (https=)
AU (1) AU2003302925A1 (https=)
BR (1) BR0316948A (https=)
CA (1) CA2509042A1 (https=)
MX (1) MXPA05006272A (https=)
WO (1) WO2004052848A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329656B2 (en) 2004-10-08 2008-02-12 H. Lundbeck A/S Arylthiobenzylpiperidine derivatives
US7446204B2 (en) 2004-10-08 2008-11-04 H. Lundbeck A/S Amino substituted aryloxybenzylpiperidine derivatives
US7902356B2 (en) 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
EP1896413B1 (en) 2005-03-28 2015-04-22 Semiconductor Energy Laboratory Co., Ltd. Anthracene derivative, material for light emitting element, light emitting element, light emitting device, and electronic device
US7731377B2 (en) * 2006-03-21 2010-06-08 Semiconductor Energy Laboratory Co., Ltd. Backlight device and display device
US7772162B2 (en) 2006-03-27 2010-08-10 Board Of Regents, The University Of Texas System Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells
US20070225176A1 (en) * 2006-03-27 2007-09-27 Pope Gary A Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells
EP2402320A1 (en) * 2006-03-31 2012-01-04 Novartis AG Anorectic agents
EP2054383A2 (en) 2006-08-09 2009-05-06 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
WO2008026614A1 (en) 2006-08-30 2008-03-06 Semiconductor Energy Laboratory Co., Ltd. Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device
WO2008118243A1 (en) * 2007-03-23 2008-10-02 Board Of Regents, The University Of Texas System Method for treating a formation with a solvent
US7723722B2 (en) * 2007-03-23 2010-05-25 Semiconductor Energy Laboratory Co., Ltd. Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative
EP2134806A4 (en) * 2007-03-23 2011-08-03 Univ Texas METHOD FOR TREATING A CARBON HYDROGEN INFORMATION
US20080286445A1 (en) * 2007-05-17 2008-11-20 Semiconductor Energy Laboratory Co., Ltd. Composition, and method of fabricating light-emitting element
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
MX2010005870A (es) * 2007-11-30 2010-08-02 Univ Texas Metodos para mejorar la productividad de pozos productores de petroleo.
WO2010005066A1 (en) * 2008-07-08 2010-01-14 Semiconductor Energy Laboratory Co., Ltd. Carbazole derivative, light-emitting element material, light-emitting element, and light-emitting device
KR101661328B1 (ko) * 2008-09-19 2016-09-29 가부시키가이샤 한도오따이 에네루기 켄큐쇼 카르바졸 유도체 및 그 제조 방법
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR102844041B1 (ko) 2016-02-26 2025-08-11 가부시키가이샤 한도오따이 에네루기 켄큐쇼 유기 화합물, 발광 소자, 발광 장치, 전자 기기, 및 조명 장치
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2025101724A1 (en) 2023-11-09 2025-05-15 Chevron Phillips Chemical Company Lp Systems and methods for chromium catalyst activation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535330A (en) 1968-04-29 1970-10-20 Sandoz Ag 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof
US3928449A (en) 1969-04-03 1975-12-23 Sandoz Ag Aminoalkoxy-terphenyls and the salts thereof
LU78484A1 (de) 1977-11-10 1979-06-13 Ciba Geigy Ag Verfahren zur herstellung von benzoxazolyl-phenyl-stilbenen
DE2752361A1 (de) 1977-11-24 1979-06-07 Troponwerke Gmbh & Co Kg Neue indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist

Also Published As

Publication number Publication date
CA2509042A1 (en) 2004-06-24
WO2004052848A1 (en) 2004-06-24
US7132456B2 (en) 2006-11-07
US20060052449A1 (en) 2006-03-09
MXPA05006272A (es) 2005-08-19
AU2003302925A1 (en) 2004-06-30
JP2006509801A (ja) 2006-03-23
EP1572637A1 (en) 2005-09-14
CN1726189A (zh) 2006-01-25

Similar Documents

Publication Publication Date Title
BR0316948A (pt) Composto, formulação farmacêutica, e, uso de um composto
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0408990A (pt) derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
SE0001899D0 (sv) New compounds
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BRPI0416628A (pt) uso de compostos orgánicos
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0409211A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
WO2003048164A3 (en) Adenosine a2a receptor antagonists
BRPI0407097A (pt) Antagonista do casr
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
BRPI0415713A (pt) mio-inositol hexafosfato para uso tópico
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
BRPI0517425A (pt) composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto
BRPI0408295A (pt) uso de um composto
TW200603787A (en) Topical preparations containing ambroxol
SE0102440D0 (sv) New compound
TW200606164A (en) New compounds
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]